{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06511882",
            "orgStudyIdInfo": {
                "id": "MCC-22191"
            },
            "organization": {
                "fullName": "H. Lee Moffitt Cancer Center and Research Institute",
                "class": "OTHER"
            },
            "briefTitle": "Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD",
            "officialTitle": "Discontinuation of Hypomethylating Agent and Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Who Have Achieved Negative Measurable Residual Disease (MRD)",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "discontinuation-of-hypomethylating-agent-and-venetoclax-in-patients-with-aml-mrd"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-07-16",
            "studyFirstSubmitQcDate": "2024-07-16",
            "studyFirstPostDateStruct": {
                "date": "2024-07-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-16",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "H. Lee Moffitt Cancer Center and Research Institute",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "AbbVie",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this research study is to see if people whose Acute myeloid leukemia (AML) is being successfully treated with azacitidine or decitabine in combination with venetoclax can discontinue this chemotherapy for some period of time after a year of treatment without increasing the likelihood that their AML will return."
        },
        "conditionsModule": {
            "conditions": [
                "Acute Myeloid Leukemia"
            ],
            "keywords": [
                "AML"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 37,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Consolidation and Discontinuation",
                    "type": "OTHER",
                    "description": "Consolidation: Patient will receive HMA (azacitidine or decitabine)/VEN (venetoclax) as part of standard of care treatment.\n\nAt the conclusion of consolidation, if the results of the bone marrow biopsy are a negative Measurable Residual Disease (MRD), patient will continue to Discontinuation.\n\nDiscontinuation:\n\nMonthly clinic visits with laboratory assessment and bone marrow biopsies (BMBs) with MRD testing every 3 months to closely monitor disease status. At any point of the study if molecular relapse (including MRD emergence), or morphologic relapse, therapy will be reinitiated.\n\nIf only molecular relapse, HMA (azacitidine or decitabine)/VEN (venetoclax) will be reinitiated with the same monitoring schedule as before.\n\nIf morphologic relapse, HMA (azacitidine or decitabine)/VEN (venetoclax) will be reinitiated for 2 cycles.\n\nIf no response (NR), patient will be taken off Study.",
                    "interventionNames": [
                        "Drug: Azacitidine",
                        "Drug: Decitabine",
                        "Drug: Venetoclax"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Azacitidine",
                    "description": "Standard of Care Intravenous (IV) infusion",
                    "armGroupLabels": [
                        "Consolidation and Discontinuation"
                    ],
                    "otherNames": [
                        "Vidaza"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Decitabine",
                    "description": "Standard of Care Intravenous (IV) infusion",
                    "armGroupLabels": [
                        "Consolidation and Discontinuation"
                    ],
                    "otherNames": [
                        "DACOGEN"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Venetoclax",
                    "description": "Standard of Care PO (By Mouth)",
                    "armGroupLabels": [
                        "Consolidation and Discontinuation"
                    ],
                    "otherNames": [
                        "Venclexta"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Rates of Complete Response (CR)/Complete Response with incomplete hematologic recovery (CRi)",
                    "description": "Rates of CR/CRi at 18 months from the time of initial CR/CRi in patients who discontinue frontline HMA (azacitidine or decitabine)/VEN (venetoclax) after achieving Measurable Residual Disease (MRD) negativity by MFC within 12 months of starting therapy.\n\nThe Null hypothesis (p0) will be tested against the alternative hypothesis (p1).\n\nNull hypothesis: p0 \u2264 50% will remain in CR/CRi at 18 months from the time of initial CR/CRi Alternative hypothesis: p1 \u2265 70% will remain in CR/CRi at 18 months from the time of initial CR/CRi",
                    "timeFrame": "Up to 18 Months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Overall Survival (OS)",
                    "description": "Overall survival will be assessed in MRD-negative patients who discontinue HMA (azacitidine or decitabine)/VEN (venetoclx).\n\nOverall Survival (OS) is defined as the length of time from the start of treatment until death due to any cause.",
                    "timeFrame": "Up to 36 Months"
                },
                {
                    "measure": "Rates to Re-Treatment",
                    "description": "Rates to re-treatment is defined as Measurable Residual Disease (MRD)-negative CR/CRi and CR/CRi and rates to re-treatment following molecular or morphologic relapse duration discontinuation.",
                    "timeFrame": "Up to 36 Months"
                },
                {
                    "measure": "Treatment Free Molecular Remission (TFMR)",
                    "description": "Defined as time from Measurable Residual Disease (MRD) negativity to first MRD positivity",
                    "timeFrame": "Up to 36 Months"
                },
                {
                    "measure": "European Organization for Research and Treatment of Cancer (EORTC-QLQ-C30)/Quality of Life (QoL)",
                    "description": "EORTC-QLQ-C30/QoL consists of a 30-item subject self-report questionnaire composed of five functional scales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties).\n\nScale scores range from 0-100.",
                    "timeFrame": "Day 1 (start of enrollment), start of Discontinuation Phase, and monthly until EOT (Up to 36 Months)"
                },
                {
                    "measure": "Patient Reported Outcome Measurement Information System (PROMIS)",
                    "description": "PROMIS scale provides response options 1-5 to indicate patient-reported health status measures for physical, mental, and social well-being.\n\nIt measures concepts such as pain, fatigue, physical function, depression, anxiety, and social function.",
                    "timeFrame": "Day 1 (start of enrollment), start of Discontinuation Phase, and monthly until EOT (Up to 36 Months)"
                },
                {
                    "measure": "EuroQoL-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analog Scale (VAS)",
                    "description": "EQ-5D-5L VAS is an instrument for measuring the general health status of an individual. It consists of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.\n\nScale scores range from 0-100.",
                    "timeFrame": "Day 1 (start of enrollment), start of Discontinuation Phase, and monthly until EOT (Up to 36 Months)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Adults 18 years of age or older at the time of obtaining informed consent.\n* Diagnosed with Acute Myeloid Leukemia (AML) (non-M3) as defined by 2016 World Health Organization (WHO)\n* Eastern Cooperative Group (ECOG) performance status score \u2264 2\n* Currently on frontline therapy with HMA (azacitidine or decitabine)/VEN and achieved Complete Remission (CR)/Complete Remission with incomplete marrow recovery (CRi) with MRD negativity defined as \\< 0.1% by Multiparameter Flow Cytometry (MFC)\n* Within 12 months of starting HMA (azacitidine or decitabine)/VEN\n* Ineligible for or declined allogeneic hematopoietic cell transplantation (HCT)\n* Ability to understand and the willingness to sign a written informed consent document\n* Must agree to adhere to the study visit schedule and other protocol requirements\n* Patients must be able to provide adequate Bone Marrow (BM) aspirate and biopsy specimens for histopathological and Measurable Residual Disease analysis during the screening procedure\n\nExclusion Criteria:\n\n* Use of cytotoxic chemotherapeutic agents, or experimental agents (agents that are not commercially available) for the treatment of AML within 28 days, or 5 half-lives, at the start of the study. Only patients who are receiving frontline HMA (azacitidine or decitabine)/VEN are potentially eligible, but if they had received a course of hydroxyurea prior to achieving CR/CRi, this is allowed.\n* Any serious medical condition or uncontrolled current illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or will place the subject at unacceptable risk if he/she participates in the study. Controlled infections or other medical conditions on long-term therapy is allowed.\n* Patients who harbored TP53 mutation at diagnosis\n* AML with extramedullary involvement including central nervous system (CNS) involvement, myeloid sarcoma, and leukemia cutis requiring directed therapy at the time of enrollment.\n* Patient is pregnant.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Gina Bellenger",
                    "role": "CONTACT",
                    "phone": "813-745-6138",
                    "email": "Gina.Bellenger@moffitt.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Onyee Chan, MD",
                    "affiliation": "Moffitt Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Moffitt Cancer Center",
                    "status": "RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33612",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Gina Bellenger",
                            "role": "CONTACT",
                            "phone": "813-745-6138",
                            "email": "Gina.Bellenger@moffitt.org"
                        },
                        {
                            "name": "Onyee Chan, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Rami Komrokji, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Timothy Kubal, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Andrew Kuykendall, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Jeffrey Lancet, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Eric Padron, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "David Sallman, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Alison Walker, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Moffitt Cancer Center Clinical Trials Website",
                    "url": "http://www.moffitt.org/clinical-trials-research/clinical-trials/"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007938",
                    "term": "Leukemia"
                },
                {
                    "id": "D000007951",
                    "term": "Leukemia, Myeloid"
                },
                {
                    "id": "D000015470",
                    "term": "Leukemia, Myeloid, Acute"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "asFound": "Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20497",
                    "name": "Neoplasm, Residual",
                    "relevance": "LOW"
                },
                {
                    "id": "M10955",
                    "name": "Leukemia, Myeloid",
                    "asFound": "Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18127",
                    "name": "Leukemia, Myeloid, Acute",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3995",
                    "name": "Myeloid Leukemia",
                    "asFound": "Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T182",
                    "name": "Acute Myeloid Leukemia",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T188",
                    "name": "Acute Non Lymphoblastic Leukemia",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001374",
                    "term": "Azacitidine"
                },
                {
                    "id": "D000077209",
                    "term": "Decitabine"
                },
                {
                    "id": "C000579720",
                    "term": "Venetoclax"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M249656",
                    "name": "Venetoclax",
                    "asFound": "0.1",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4673",
                    "name": "Azacitidine",
                    "asFound": "Pilot Study",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1697",
                    "name": "Decitabine",
                    "asFound": "Derived",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}